Eli Lilly & Co. (LLY) to Charge $2,100 Per Dose of Bebtelovimab Antibody Drug - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly & Co. (LLY) Shares Slide After Missing Estimates
August 4, 2022 11:06 AM EDTEli Lilly & Co. (NYSE: LLY) shares are down Thursday following its second-quarter earnings report, which saw it miss analyst estimates.
The drugmaker reported earnings of $1.25 per share, $0.46 below the analyst estimate of $1.71, while revenue came in at $6.49 billion versus the consensus estimate of $6.85... More
